Clinical Trials Sponsored by Huot, Celine, M.D.

Total 92 results

Huot, Celine, M.D.

Completed

Use of a Telehomecare Program for Young Patients With New Onset Type 1 Diabetes

Diabetes Mellitus, Type 1

Canada
M.D. Anderson Cancer Center
Celgene

Completed

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Melanoma

United States
M.D. Anderson Cancer Center
Celgene

Completed

Azacitidine and CAPOX in Metastatic Colorectal Cancer

Colorectal Cancer

United States
M.D. Anderson Cancer Center
Celgene

Completed

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

Leukemia | AML | MDS

United States
M.D. Anderson Cancer Center
Celgene

Completed

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL

United States
M.D. Anderson Cancer Center
Celgene

Completed

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Leukemia

United States
M.D. Anderson Cancer Center
Celgene

Completed

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Advanced Cancers

United States
M.D. Anderson Cancer Center
Celgene

Terminated

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Myeloma

United States
M.D. Anderson Cancer Center
Celgene

Terminated

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

Malignant Gliomas

United States
M.D. Anderson Cancer Center
Celgene

Completed

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Colorectal Cancer | Cancer of Gastrointestinal Tract

United States
M.D. Anderson Cancer Center
Celgene

Completed

Pomalidomide for Myelofibrosis Patients

Polycythemia Vera | Thrombocythemia

United States
M.D. Anderson Cancer Center
Celgene

Completed

Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
Celgene

Completed

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

Prostate Cancer

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Lymphoma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide for Patients With Myelofibrosis (MF)

Myelofibrosis

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

Melanoma | Brain Neoplasms

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Thalidomide-Dexamethasone for Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Hematologic Disorder

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Paclitaxel in Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

The Effects of Thalidomide on Symptom Clusters

Advanced Cancers

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Advanced Cancers

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Phase II 5-Azacytidine Plus VPA Plus ATRA

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

Glioma | Glioblastoma Multiforme

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Thalidomide for Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma

Melanoma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Melanoma | Liver Metastasis

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Graft-versus-Host Disease

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain

Pain | Advanced Cancer

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)

Leukemia | Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

A Phase II Study of CC-5013 in Myelofibrosis

Myelofibrosis

United States
Levine, Gary M. , M.D.
Hologic, Inc.

Unknown

An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging

Breast Cancer

United States
M.D. Anderson Cancer Center
Celgene Corporation

Active, not recruiting

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

Solid Tumors

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Ph II Study of Azacitidine in Myelofibrosis

Myelofibrosis

United States
M.D. Anderson Cancer Center
Celgene Corporation; Amgen

Completed

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Celgene

Completed

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Celgene; Onyx Therapeutics, Inc.

Terminated

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals; Celgene Corporation

Completed

PKC412 and 5-Azacytidine

Leukemia

United States

Clinical Trials Sponsored by Huot, Celine, M.D.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations